Download

Download Full Text (325 KB)

Contents

  • FGFR Inhibition for Bladder Cancer: Erdafitinib has favorable response rate in advanced bladder cancers, including those that do not respond to immunotherapy
  • INBRIEF: Targeted Therapies Matched to Tumor-Specific Mutations Prolong Survival
  • Managing High-Risk Breast Lesions: Strong provider recommendation for preventive therapy increases its use in women with lobular carcinoma in situ, atypical hyperplasia
  • Aerosolized Gemcitabine for Pulmonary Metastases: Clinical trials tests novel chemotherapy delivery system for patients with lung metastases from osteosarcoma or other solid tumors
  • HOUSE CALL: What the national Cancer Institute Does- Resources for cancer patients, caregivers, physicians, researchers

Publication Date

7-1-2018

Publisher

The University of Texas MD Anderson Cancer Center

City

Houston, Texas

Keywords

National Cancer Institute (U.S.); Siefker-Radtke, Arlene; Tsimberidou, Apostolia-Maria; Brewster, Abenaa M.; Bevers, Therese; Kleinerman, Eugenie; Gordon, Nancy; Bitar, Najat Daw; Urinary Bladder Neoplasms; Fibroblast Growth Factors; erdafitinib; Clinical Trials as Topic; Molecular Targeted Therapy; Mutation; Breast Carcinoma In Situ; Breast Neoplasms; Lung Neoplasms -- secondary; Osteosarcoma; Gemcitabine.

Disciplines

History of Science, Technology, and Medicine | Oncology

Conditions Governing Access

Redacted

OncoLog, Volume 63, Number 07, July 2018

Share

COinS